Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer.

Kershaw MH, Jackson JT, Haynes NM, Teng MW, Moeller M, Hayakawa Y, Street SE, Cameron R, Tanner JE, Trapani JA, Smyth MJ, Darcy PK.

J Immunol. 2004 Aug 1;173(3):2143-50.

2.

A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.

Moeller M, Haynes NM, Trapani JA, Teng MW, Jackson JT, Tanner JE, Cerutti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK.

Cancer Gene Ther. 2004 May;11(5):371-9.

PMID:
15060573
3.

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.

Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, Sayers TJ, Seki N, Okumura K, Yagita H, Smyth MJ.

J Exp Med. 2004 Feb 16;199(4):437-48. Epub 2004 Feb 9.

4.

Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway.

Westwood JA, Kelly JM, Tanner JE, Kershaw MH, Smyth MJ, Hayakawa Y.

J Immunol. 2004 Jan 15;172(2):757-61.

5.

Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.

Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H, Tanner JE, Smyth MJ, Sayers TJ.

Cancer Res. 2003 Jan 1;63(1):207-13.

Supplemental Content

Loading ...
Support Center